HypertensionNCT07887542
Effect of Home and Remote Blood Pressure Monitoring Via Home BP Monitoring System (HMS) on Adults With Hypertension in Taiwan
A study testing Case-manager surveillance with physician-guided remote titration and Passive data review at clinic visits in people with Hypertension, run by National Taiwan University Hospital Hsin-Chu Branch at 1 site in Taiwan.
Trial summary
The goal of this clinical trial is to learn whether adding case-manager support to app-connected home blood pressure monitoring improves blood pressure control in adults with hypertension. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Hypertension
- What is being tested?
- Case-manager surveillance with physician-guided remote titration and Passive data review at clinic visits
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 211 participants
- Where
- 1 siteTaiwan
- Study dates
- 6 Oct 2022to 21 Oct 2025
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Willing to provide written informed consent.
- Age 18 years or older. Age 18 years or older. (Participants enrolled before approval of protocol version 4 in February 2023 were required to be 20 to 80 years old.)
- Patients receiving antihypertensive medication who have not achieved the treatment target of office blood pressure <130/80 mmHg, or patients with newly diagnosed hypertension with office systolic blood pressure of 140-180 mmHg and diastolic blood pressure of 90-110 mmHg (or 24-hour ambulatory blood pressure >130/80 mmHg).
Who cannot join
- End-stage, incurable disease with life expectancy of less than one year.
- Women who are pregnant, may be pregnant, or are breastfeeding.
- Dementia or loss of most self-care ability (ECOG performance status 2 or above).
- Office blood pressure >180/110 mmHg.
- Documented cardiac arrhythmia.
- Diagnosed secondary hypertension.
- Inability to use a smartphone.
- Acute cardiovascular event within the past six months, including stroke, decompensated heart failure, percutaneous coronary intervention, or coronary artery bypass graft surgery.
Trial locations and contacts
1 site in 1 country.
About this study
Official title: Effect of Home and Remote Blood Pressure Monitoring Via Home BP Monitoring System (HMS) on Adults With Hypertension in Taiwan: Randomized Clinical Trial
The goal of this clinical trial is to learn whether adding case-manager support to app-connected home blood pressure monitoring improves blood pressure control in adults with hypertension.
The main questions it aims to answer are:
Read more
- Does case-manager surveillance with physician-guided medication adjustment lower office, home, and 24-hour ambulatory blood pressure more than home monitoring with review of readings only at clinic visits?
- Does it change how consistently participants measure their blood pressure at home, how their blood pressure medicines are adjusted, and how often side effects are reported?
All participants received the same Bluetooth upper-arm blood pressure monitor linked to a smartphone app (OMRON Home BP Monitoring System, HMS). They measured their blood pressure at home in the first week of every month, following the Taiwan "722" schedule: 7 consecutive days, morning and evening, 2 readings each time.
Each participant spent 6 months in each of two conditions, in a randomly assigned order:
- Case-manager period: case managers reviewed the home readings every month, contacted participants, and arranged earlier clinic visits for medication adjustment when readings met predefined criteria.
- Control period: home readings were stored and reviewed by the cardiologist only at scheduled clinic visits.
Participants attended clinic visits at the start of the study and at 3, 6, 9, and 12 months.
Read the detailed description
Design and setting:
This is a single-center, open-label, randomized, two-period, two-sequence crossover trial conducted at the cardiology outpatient clinics of National Taiwan University Hospital Hsin-Chu Branch, Hsinchu, Taiwan. Participants were randomized 1:1 to receive the case-manager intervention for months 0-6 followed by the control condition for months 6-12, or the reverse order. Crossover occurred at 6 months without a washout period.
Home monitoring common to both conditions:
At enrollment, every participant received an upper-arm Bluetooth blood pressure monitor (OMRON HEM-7157T) paired with the HMS smartphone application. The application transmitted every reading automatically, provided a log for medication intake and side effects, and delivered the same system-generated educational messages and reminders in both conditions. Participants were trained to follow the Taiwan 722 home blood pressure protocol in the first week of each month; measurement at other times was allowed.
Intervention condition (case-manager surveillance with physician-guided remote titration):
Cardiovascular case managers reviewed the transmitted readings at the beginning of each month against two targets: home blood pressure below 130/80 mmHg and self-reported medication adherence on more than 50% of days. A predefined algorithm specified: telephone counseling when participants measured on fewer than 4 days, reported adherence below 50%, or reported side effects; a clinic visit within 2 weeks for home blood pressure above 180/110 mmHg; doubling of the current dose or addition of a drug class when home blood pressure exceeded 135/85 or 145/90 mmHg, respectively, for 2 consecutive months; a change in dosing time or frequency for morning-only or evening-only elevation; and withdrawal of a drug class for home systolic blood pressure below 110 mmHg. All prescription changes were made by the cardiologist at a clinic visit, scheduled earlier when the algorithm required it, and recorded in the medical record.
Control condition (passive data review):
Readings were stored but not reviewed between visits. At each scheduled clinic visit, the treating cardiologist received a summary of the home readings from the preceding 2 weeks and adjusted treatment at his or her discretion.
Assessments:
Office blood pressure was measured at enrollment and at 3, 6, 9, and 12 months. 24-hour ambulatory blood pressure monitoring, brachial-ankle pulse wave velocity, and blood and urine tests were performed at enrollment and at approximately 6 and 12 months. Medication changes, side-effect reports, and health care use were recorded throughout.
Analysis:
Treatment effects are estimated as the 6-month (period 1) difference between randomized sequences, adjusted for baseline values, and as the within-participant crossover treatment effect using the 6- and 12-month values. The sequence effect is examined as an indicator of carryover.
This trial was registered retrospectively, after enrollment was completed.
- Conditions
- Hypertension
- Being tested
- Case-manager surveillance with physician-guided remote titration, Passive data review at clinic visits
- Keywords
- Home blood pressure monitoring, Blood pressure telemonitoring, Case management, Antihypertensive medication titration, Ambulatory blood pressure monitoring, Mobile health, Crossover trial
- Medical subject headings
- Hypertension
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Case-manager surveillance with physician-guided remote titrationOther
Participants measure home blood pressure with an OMRON HEM-7157T Bluetooth monitor linked to the Home BP Monitoring System (HMS) app, following the Taiwan 722 protocol in the first week of each month. Case managers review the transmitted readings monthly against targets of home BP <130/80 mmHg and medication adherence >50% of days. A predefined algorithm guides telephone counseling (fewer than 4 measurement days, adherence <50%, or side effects), a clinic visit within 2 weeks (home BP >180/110 mmHg), dose doubling or addition of a drug class (home BP >135/85 or >145/90 mmHg for 2 consecutive months), dosing time or frequency changes (morning-only or evening-only elevation), and drug withdrawal (home systolic BP <110 mmHg). All prescription changes are made by the cardiologist at a clinic visit, scheduled earlier when needed.
Passive data review at clinic visitsOther
Participants use the same monitor and app and follow the same 722 measurement protocol. Readings are stored but not reviewed between visits, and no case-manager contact is provided. At each scheduled clinic visit, the treating cardiologist receives a summary of the home readings from the preceding 2 weeks and adjusts treatment at his or her discretion. The app delivers the same system-generated education messages and reminders as in the intervention period.
| Study group | Role | What they receive |
|---|---|---|
| Case Management First, Then Passive Review | Experimental | Months 0-6: case-manager surveillance with physician-guided remote titration. Months 6-12: passive review of home readings at clinic visits. Crossover at month 6 without a washout period. The same app-connected home blood pressure monitor was used throughout. Receives: Other: Case-manager surveillance with physician-guided remote titration; Other: Passive data review at clinic visits |
| Passive Review First, Then Case Management | Experimental | Months 0-6: passive review of home readings at clinic visits. Months 6-12: case-manager surveillance with physician-guided remote titration. Crossover at month 6 without a washout period. The same app-connected home blood pressure monitor was used throughout. Receives: Other: Case-manager surveillance with physician-guided remote titration; Other: Passive data review at clinic visits |
What is being measured
The primary outcome is the main question the study is designed to answer.
Office Systolic Blood Pressure
Office systolic blood pressure (mmHg) measured at the clinic visit, compared between the case-manager surveillance and passive data review conditions of the crossover design.
Measured: Baseline, month 6, month 12
Office Diastolic Blood Pressure
Office diastolic blood pressure (mmHg) measured at the clinic visit, compared between the case-manager surveillance and passive data review conditions of the crossover design.
Measured: Baseline, month 6, month 12
Home Systolic Blood Pressure
Mean home systolic blood pressure (mmHg), measured with the Omron HEM-7157T according to the 722 protocol: on 7 consecutive days at the start of each month, 2 sessions per day (morning and evening), 2 readings per session. Values are compared between the case-manager surveillance and passive data review conditions of the crossover design.
Measured: Baseline, month 6, month 12
Home Diastolic Blood Pressure
Mean home diastolic blood pressure (mmHg) measured with the Omron HEM-7157T according to the 722 protocol (7 consecutive days at the start of each month, morning and evening, 2 readings per session), compared between the case-manager surveillance and passive data review conditions of the crossover design.
Measured: Baseline, month 6, month 12
24-Hour Mean Systolic Blood Pressure
Mean 24-hour systolic blood pressure (mmHg) on ambulatory blood pressure monitoring, compared between the case-manager surveillance and passive data review conditions of the crossover design.
Measured: Baseline, month 6, month 12
24-Hour Mean Diastolic Blood Pressure
Mean 24-hour diastolic blood pressure (mmHg) on ambulatory blood pressure monitoring, compared between the case-manager surveillance and passive data review conditions of the crossover design.
Measured: Baseline, month 6, month 12
Secondary outcomes (9)
Brachial-Ankle Pulse Wave Velocity
Brachial-ankle pulse wave velocity (m/s), measured with an automated oscillometric device, as a measure of arterial stiffness (target-organ damage).
Measured: Baseline, month 6, month 12
Number of Participants With Adverse Reactions Leading to Treatment Discontinuation
Participants with adverse reactions to antihypertensive treatment that led to discontinuation of a medication, recorded in the app or at clinic visits.
Measured: Up to month 12
Urine Albumin-to-Creatinine Ratio
Urine albumin-to-creatinine ratio (mg/g), as a measure of microalbuminuria (target-organ damage).
Measured: Baseline, month 6, month 12
ECG Voltage
Sokolow-Lyon voltage (SV1 + RV5 or RV6, mV) on 12-lead ECG, as a measure of left ventricular hypertrophy (target-organ damage).
Measured: Baseline, month 6, month 12
Adherence to the Home Blood Pressure Measurement Protocol
Percentage of days per week on which both the morning and evening measurement sessions were completed, calculated from readings transmitted by the app.
Measured: Weekly, from baseline to month 12
Retinal Nerve Fiber Layer Thickness
Average retinal nerve fiber layer thickness (µm) measured by optical coherence tomography, as a measure of retinal microvascular damage.
Measured: Baseline
Number of Cardiology Clinic Visits
Number of cardiology outpatient visits per participant, from hospital records.
Measured: Months 0-6 and months 6-12
Number of Emergency Department Visits
Number of emergency department visits per participant, from hospital records.
Measured: Months 0-6 and months 6-12
Number of Hospital Admissions
Number of hospital admissions per participant, from hospital records.
Measured: Months 0-6 and months 6-12
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted21 Oct 2026
- Study start6 Oct 2022
- Primary completion21 Oct 2025
- Study completion21 Oct 2025
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for HypertensionStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Health services research
- Allocation
- Randomised
- Intervention model
- Crossover
- Model description
- Randomized, open-label, two-period, two-sequence crossover design. All participants used the same app-connected home blood pressure monitor throughout. Participants were randomized 1:1 to case-manager surveillance with physician-guided remote titration for months 0-6 followed by passive review of home readings at clinic visits for months 6-12, or the reverse order. Crossover occurred at month 6 without a washout period. Assessments were performed at baseline and at months 3, 6, 9, and 12.
- Masking
- None (open label)
- Enrolment
- 211 participants (actual)
Sponsor and investigators
- Lead sponsor
- National Taiwan University Hospital Hsin-Chu Branch
- Sponsor type
- University, hospital or other
- Collaborators
- Omron Healthcare Co., Ltd.
- Responsible party
- Sponsor
- Investigators
- Chih-Kuo Lee, MD, Principal investigator, National Taiwan University Hospital Hsin-Chu Branch
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07887542
- Sponsor's protocol ID
- 111-006-F
- Status last verified
- Oct 2026
- First submitted
- 27 Aug 2023
- Last updated
- 21 Oct 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Yes: De-identified individual participant data underlying the published results (office, home, and ambulatory blood pressure, medication changes, and side-effect reports) will be available on reasonable request to the principal investigator, after approval of a research proposal and subject to approval by the Research Ethics Committee of National Taiwan University Hospital Hsin-Chu Branch and a data use agreement.
Study at a glance
From the registry record, last updated by the sponsor on 21 Oct 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Effect of Home and Remote Blood Pressure Monitoring Via Home BP Monitoring System (HMS) on Adults With Hypertension in Taiwan: Randomized Clinical Trial
- ClinicalTrials.gov ID
- NCT07887542
- Acronym / sponsor ID
- 111-006-F
- Conditions
- Hypertension
- Keywords
- Home blood pressure monitoring, Blood pressure telemonitoring, Case management, Antihypertensive medication titration, Ambulatory blood pressure monitoring, Mobile health, Crossover trial
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 211 participants (actual)
- Lead sponsor
- National Taiwan University Hospital Hsin-Chu BranchUniversity, hospital or other
- Collaborators
- Omron Healthcare Co., Ltd.
- Study start
- 6 Oct 2022 (actual)
- Primary completion
- 21 Oct 2025 (actual)
- Study completion
- 21 Oct 2025 (actual)
- First posted
- 21 Oct 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The goal of this clinical trial is to learn whether adding case-manager support to app-connected home blood pressure monitoring improves blood pressure control in adults with hypertension.
The main questions it aims to answer are:
- Does case-manager surveillance with physician-guided medication adjustment lower office, home, and 24-hour ambulatory blood pressure more than home monitoring with review of readings only at clinic visits?
- Does it change how consistently participants measure their blood pressure at home, how their blood pressure medicines are adjusted, and how often side effects are reported?
All participants received the same Bluetooth upper-arm blood pressure monitor linked to a smartphone app (OMRON Home BP Monitoring System, HMS). They measured their blood pressure at home in the first week of every month, following the Taiwan "722" schedule: 7 consecutive days, morning and evening, 2 readings each time.
Each participant spent 6 months in each of two conditions, in a randomly assigned order:
- Case-manager period: case managers reviewed the home readings every month, contacted participants, and arranged earlier clinic visits for medication adjustment when readings met predefined criteria.
- Control period: home readings were stored and reviewed by the cardiologist only at scheduled clinic visits.
Participants attended clinic visits at the start of the study and at 3, 6, 9, and 12 months.
Detailed description
Design and setting:
This is a single-center, open-label, randomized, two-period, two-sequence crossover trial conducted at the cardiology outpatient clinics of National Taiwan University Hospital Hsin-Chu Branch, Hsinchu, Taiwan. Participants were randomized 1:1 to receive the case-manager intervention for months 0-6 followed by the control condition for months 6-12, or the reverse order. Crossover occurred at 6 months without a washout period.
Home monitoring common to both conditions:
At enrollment, every participant received an upper-arm Bluetooth blood pressure monitor (OMRON HEM-7157T) paired with the HMS smartphone application. The application transmitted every reading automatically, provided a log for medication intake and side effects, and delivered the same system-generated educational messages and reminders in both conditions. Participants were trained to follow the Taiwan 722 home blood pressure protocol in the first week of each month; measurement at other times was allowed.
Intervention condition (case-manager surveillance with physician-guided remote titration):
Cardiovascular case managers reviewed the transmitted readings at the beginning of each month against two targets: home blood pressure below 130/80 mmHg and self-reported medication adherence on more than 50% of days. A predefined algorithm specified: telephone counseling when participants measured on fewer than 4 days, reported adherence below 50%, or reported side effects; a clinic visit within 2 weeks for home blood pressure above 180/110 mmHg; doubling of the current dose or addition of a drug class when home blood pressure exceeded 135/85 or 145/90 mmHg, respectively, for 2 consecutive months; a change in dosing time or frequency for morning-only or evening-only elevation; and withdrawal of a drug class for home systolic blood pressure below 110 mmHg. All prescription changes were made by the cardiologist at a clinic visit, scheduled earlier when the algorithm required it, and recorded in the medical record.
Control condition (passive data review):
Readings were stored but not reviewed between visits. At each scheduled clinic visit, the treating cardiologist received a summary of the home readings from the preceding 2 weeks and adjusted treatment at his or her discretion.
Assessments:
Office blood pressure was measured at enrollment and at 3, 6, 9, and 12 months. 24-hour ambulatory blood pressure monitoring, brachial-ankle pulse wave velocity, and blood and urine tests were performed at enrollment and at approximately 6 and 12 months. Medication changes, side-effect reports, and health care use were recorded throughout.
Analysis:
Treatment effects are estimated as the 6-month (period 1) difference between randomized sequences, adjusted for baseline values, and as the within-participant crossover treatment effect using the 6- and 12-month values. The sequence effect is examined as an indicator of carryover.
This trial was registered retrospectively, after enrollment was completed.
Study design
- Primary purpose
- Health services research
- Allocation
- Randomised
- Intervention model
- Crossover
- Masking
- None (open label)
- Number of arms
- 2
- Model description
- Randomized, open-label, two-period, two-sequence crossover design. All participants used the same app-connected home blood pressure monitor throughout. Participants were randomized 1:1 to case-manager surveillance with physician-guided remote titration for months 0-6 followed by passive review of home readings at clinic visits for months 6-12, or the reverse order. Crossover occurred at month 6 without a washout period. Assessments were performed at baseline and at months 3, 6, 9, and 12.
| Arm | Type | Receives |
|---|---|---|
| Case Management First, Then Passive Review | Experimental | Other: Case-manager surveillance with physician-guided remote titration, Other: Passive data review at clinic visitsMonths 0-6: case-manager surveillance with physician-guided remote titration. Months 6-12: passive review of home readings at clinic visits. Crossover at month 6 without a washout period. The same app-connected home blood pressure monitor was used throughout. |
| Passive Review First, Then Case Management | Experimental | Other: Case-manager surveillance with physician-guided remote titration, Other: Passive data review at clinic visitsMonths 0-6: passive review of home readings at clinic visits. Months 6-12: case-manager surveillance with physician-guided remote titration. Crossover at month 6 without a washout period. The same app-connected home blood pressure monitor was used throughout. |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (3 listed)
- Willing to provide written informed consent.
- Age 18 years or older. Age 18 years or older. (Participants enrolled before approval of protocol version 4 in February 2023 were required to be 20 to 80 years old.)
- Patients receiving antihypertensive medication who have not achieved the treatment target of office blood pressure <130/80 mmHg, or patients with newly diagnosed hypertension with office systolic blood pressure of 140-180 mmHg and diastolic blood pressure of 90-110 mmHg (or 24-hour ambulatory blood pressure >130/80 mmHg).
Key exclusion criteria (8 listed)
- End-stage, incurable disease with life expectancy of less than one year.
- Women who are pregnant, may be pregnant, or are breastfeeding.
- Dementia or loss of most self-care ability (ECOG performance status 2 or above).
- Office blood pressure >180/110 mmHg.
- Documented cardiac arrhythmia.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Case-manager surveillance with physician-guided remote titrationParticipants measure home blood pressure with an OMRON HEM-7157T Bluetooth monitor linked to the Home BP Monitoring System (HMS) app, following the Taiwan 722 protocol in the first week of each month. Case managers review the transmitted readings monthly against targets of home BP <130/80 mmHg and medication adherence >50% of days. A predefined algorithm guides telephone counseling (fewer than 4 measurement days, adherence <50%, or side effects), a clinic visit within 2 weeks (home BP >180/110 mmHg), dose doubling or addition of a drug class (home BP >135/85 or >145/90 mmHg for 2 consecutive months), dosing time or frequency changes (morning-only or evening-only elevation), and drug withdrawal (home systolic BP <110 mmHg). All prescription changes are made by the cardiologist at a clinic visit, scheduled earlier when needed. | Other | Case Management First, Then Passive Review, Passive Review First, Then Case Management |
| Passive data review at clinic visitsParticipants use the same monitor and app and follow the same 722 measurement protocol. Readings are stored but not reviewed between visits, and no case-manager contact is provided. At each scheduled clinic visit, the treating cardiologist receives a summary of the home readings from the preceding 2 weeks and adjusts treatment at his or her discretion. The app delivers the same system-generated education messages and reminders as in the intervention period. | Other | Case Management First, Then Passive Review, Passive Review First, Then Case Management |
Primary outcome
Office Systolic Blood Pressure
Time frame: Baseline, month 6, month 12
Office systolic blood pressure (mmHg) measured at the clinic visit, compared between the case-manager surveillance and passive data review conditions of the crossover design.
Office Diastolic Blood Pressure
Time frame: Baseline, month 6, month 12
Office diastolic blood pressure (mmHg) measured at the clinic visit, compared between the case-manager surveillance and passive data review conditions of the crossover design.
Home Systolic Blood Pressure
Time frame: Baseline, month 6, month 12
Mean home systolic blood pressure (mmHg), measured with the Omron HEM-7157T according to the 722 protocol: on 7 consecutive days at the start of each month, 2 sessions per day (morning and evening), 2 readings per session. Values are compared between the case-manager surveillance and passive data review conditions of the crossover design.
Home Diastolic Blood Pressure
Time frame: Baseline, month 6, month 12
Mean home diastolic blood pressure (mmHg) measured with the Omron HEM-7157T according to the 722 protocol (7 consecutive days at the start of each month, morning and evening, 2 readings per session), compared between the case-manager surveillance and passive data review conditions of the crossover design.
24-Hour Mean Systolic Blood Pressure
Time frame: Baseline, month 6, month 12
Mean 24-hour systolic blood pressure (mmHg) on ambulatory blood pressure monitoring, compared between the case-manager surveillance and passive data review conditions of the crossover design.
24-Hour Mean Diastolic Blood Pressure
Time frame: Baseline, month 6, month 12
Mean 24-hour diastolic blood pressure (mmHg) on ambulatory blood pressure monitoring, compared between the case-manager surveillance and passive data review conditions of the crossover design.
9 secondary outcomes
Brachial-Ankle Pulse Wave Velocity
Time frame: Baseline, month 6, month 12
Number of Participants With Adverse Reactions Leading to Treatment Discontinuation
Time frame: Up to month 12
Urine Albumin-to-Creatinine Ratio
Time frame: Baseline, month 6, month 12
ECG Voltage
Time frame: Baseline, month 6, month 12
Adherence to the Home Blood Pressure Measurement Protocol
Time frame: Weekly, from baseline to month 12
Retinal Nerve Fiber Layer Thickness
Time frame: Baseline
Number of Cardiology Clinic Visits
Time frame: Months 0-6 and months 6-12
Number of Emergency Department Visits
Time frame: Months 0-6 and months 6-12
Number of Hospital Admissions
Time frame: Months 0-6 and months 6-12
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 21 Oct 2026.
- Individual participant dataSharing planned: Yes. De-identified individual participant data underlying the published results (office, home, and ambulatory blood pressure, medication changes, and side-effect reports) will be available on reasonable request to the principal investigator, after approval of a research proposal and subject to approval by the Research Ethics Committee of National Taiwan University Hospital Hsin-Chu Branch and a data use agreement.
Related trials for Hypertension
Active, not recruiting
Digital Reinforcement of Motivational Interviewing Micro-Skills Among Primary Care Healthcare Professionals
Hypertension (Without Type 2 Diabetes Mellitus)
Recruiting
Investigating Vascular Properties of HEMI and SPG Signals in Individuals With or at Risk for Chronic Kidney Disease
Chronic Kidney Disease, Hypertension (HTN)
Recruiting
Trial Phase: Syndemic Adapted Medly Uganda
Mental Health
Not yet recruitingPhase 2/3
An Open-Label Extension Study to Evaluate Inhaled Treprostinil SMI in Participants With Pulmonary Hypertension Associated With Chronic Obstructive Pulmonary Disease (PH-COPD)
Pulmonary Hypertension Associated With Chronic Obstructive Pulmonary Disease
Enrolling by invitation
Testing Implementation Strategies to Support Clinic Fidelity to an Outpatient Hypertension Bundle
Pregnancy Related, Hypertension
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Chih-Kuo Lee, MD principal investigator
National Taiwan University Hospital Hsin-Chu Branch
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Case-manager surveillance with physician-guided remote titration and Passive data review at clinic visits in people with Hypertension, run by National Taiwan University Hospital Hsin-Chu Branch at 1 site in Taiwan.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 3 inclusion and 8 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 21 Oct 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Taiwan. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Office Systolic Blood Pressure (time frame: Baseline, month 6, month 12). The study lists 6 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 21 Oct 2026.